Due to the fact that melanoma cells resistant to vemurafenib maintained sensitivity to DCA, this approach suggests a possible combination therapy to overcome BRAF inhibitors resistance in patients with melanoma (Domingues et al. 2018). The gene discussed is BRAF; the disease is melanoma.